1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Seegene, Inc.
  6. News
  7. Summary
    A096530   KR7096530001

SEEGENE, INC.

(A096530)
  Report
End-of-day quote Korea Stock Exchange  -  05-16
40100.00 KRW   +2.82%
05/13Seegene reports first quarter 2022 financial results
AQ
04/26Seegene unveils world's first commercialized '3 Ct' PCR assay
AQ
04/26Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Seegene's Allplex™ SARS CoV-2 FluA/FluB/RSV Assay approved under Health Canada's Interim Order

01/17/2022 | 07:01am EDT

SEOUL, South Korea, Jan. 17, 2022 /CNW/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, announced it has received approval of its Allplex™ SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim Order on January 11.

Logo (PRNewsfoto/Seegene Inc.)

Seegene's Allplex™ SARS CoV-2 FluA/FluB/RSV Assay is a multiplex real-time PCR assay that enables simultaneous amplification and differentiation of respiratory symptoms. In a single test, it can distinguish among Influenza A, B, RSV, and COVID-19. This assay expected to play a crucial role in responding against the potential 'twindemic' as the country is forecasting a surge in both flu patients and COVID-19 patients.

To support Canada experiencing surging demand for COVID-19 tests, Seegene delivered 340,000 COVID-19 tests to Canada by a charter flight on January 13.

"Demand for COVID-19 tests is skyrocketing due to the resurgence of confirmed cases," said Ho Yi, Chief Sales and Marketing Officer of Seegene. "We are fully prepared to supply enough test kits globally and will continue to be strong global partners in the effort to manage the spread of COVID-19." This latest approval is expected to be a significant opportunity for the company, as it will allow Seegene to raise its product awareness in surrounding countries of Canada such as Latin America and others.

Visit www.seegene.com for more information.  

About Seegene, Inc.

Seegene, Inc. was founded in Seoul, South Korea in 2000 and has subsidiaries in the U.S.A., Canada, Germany, Italy, Mexico, Brazil, Colombia, and the Middle East. Seegene, Inc. is an in-vitro diagnostics (IVD) company that has been turning innovative technologies into products through its pioneering R&D activities. Seegene owns its original patent technology including DPO™ (Dual Priming Oligonucleotide) for multiple target amplification; TOCE™ for multiple target detection in a single channel; MuDT™, the world's first real-time PCR technology that provides individual Ct values for multiple targets in a single channel for quantitative assays.; and mTOCE™ multiplex mutation detection technology. With these cutting-edge molecular diagnostic (MDx) technologies applied to diagnostic kits and other tools, Seegene has enhanced the sensitivity, specificity, and disease-coverage per a test of PCR (polymerase chain reaction) to unprecedented levels by providing accurate high-multiplex PCR products that target and detect genes of multiple pathogens simultaneously per each fluorescence channel. This feature dramatically saves testing time and cost. Seegene continues to set new standards in MDx through cutting-edge innovations.

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/seegenes-allplex-sars-cov-2-fluaflubrsv-assay-approved-under-health-canadas-interim-order-301461821.html

SOURCE Seegene Inc.

© Canada Newswire, source Canada Newswire English

All news about SEEGENE, INC.
05/13Seegene reports first quarter 2022 financial results
AQ
04/26Seegene unveils world's first commercialized '3 Ct' PCR assay
AQ
04/26Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay
CI
04/06Seegene's Allplex™ RV Master Assay Receives Australian TGA Approval
CI
03/17Seegene appoints Dr. Glen Hansen as Head of Medical Affairs of U.S. subsidiary
AQ
03/04Seegene, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.
CI
03/04Seegene, Inc. authorizes a Buyback Plan.
CI
03/02Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business
AQ
02/24Seegene unveils new assay optimized for on-site testing in 'living with Covid-19' era
AQ
02/24Seegene Inc. Unveils New Assay Optimized for On-Site Testing in 'Living with Covid-19' ..
CI
More news
Financials
Sales 2022 1 322 B 1,04 B 1,04 B
Net income 2022 459 B 0,36 B 0,36 B
Net cash 2022 1 050 B 0,83 B 0,83 B
P/E ratio 2022 4,56x
Yield 2022 2,00%
Capitalization 2 068 B 1 630 M 1 630 M
EV / Sales 2022 0,77x
EV / Sales 2023 0,82x
Nbr of Employees 928
Free-Float 67,9%
Chart SEEGENE, INC.
Duration : Period :
Seegene, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEEGENE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 40 100,00 KRW
Average target price 81 500,00 KRW
Spread / Average Target 103%
EPS Revisions
Managers and Directors
Jong-Yoon Chun Chief Executive Officer & Director
Jin-Soo Choi President & General Manager-Management
Kyung-O Min President & Head-Research
Min-Chul Lee President, Head-Research & Development
Ho Lee President & Head-Sales
Sector and Competitors
1st jan.Capi. (M$)
SEEGENE, INC.-34.26%1 568
EXACT SCIENCES CORPORATION-35.05%8 894
BGI GENOMICS CO., LTD.-25.28%3 985
GUARDANT HEALTH, INC.-64.92%3 576
IOVANCE BIOTHERAPEUTICS, INC.-26.40%2 208
BEIJING STRONG BIOTECHNOLOGIES, INC.-17.66%1 429